Fennec Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results

Fennec Pharmaceuticals Inc. (FENC) reported Q2 2025 earnings, with CEO Jeff Hackman and CFO Robert Andrade discussing the financial results and business update. The company made forward-looking statements, which are subject to risks and uncertainties, and will not update or revise them without a specific obligation. The earnings call was recorded and will be available on Fennec's website for 30 days.

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) reported its Q2 2025 financial results, with CEO Jeff Hackman and CFO Robert Andrade discussing the company's performance and business outlook during an earnings call. The company achieved total net revenues of $9.7 million, representing a 33% year-over-year increase from Q2 2024. The growth was driven by significant adoption of PEDMARK® in large community practices and academic centers, as well as successful initial uptake of PEDMARQSI® in the UK and Germany.

Key highlights include the addition of PEDMARK® to a large national oncology group's formulary for patients under 40, continued expansion of the Fennec HEARS™ patient support program, and the company's strengthened patent portfolio with a new U.S. patent providing protection until 2039. Despite the revenue growth, Fennec posted a net loss of $3.2 million for Q2 2025, which was a 43% improvement from the $5.55 million loss in Q2 2024. The company's cash position stood at $18.7 million as of June 30, 2025, down from $22.7 million in Q1.

The company expects Japan Clinical Trial (STS-J01) results in the second half of 2025, which could open up the Japanese market. CEO Jeff Hackman noted, "The results demonstrate the scalability of our model and the strong demand for PEDMARK® across key segments of the market. With the U.S. momentum for PEDMARK building, coupled with Norgine’s ex-U.S. PEDMARQSI® launches and results from the investigator-initiated clinical trial STS-J01 in Japan expected in the coming months, we believe the global opportunity for both patients and Fennec shareholders is significant."

The earnings call also discussed the company's focus on the AYA (Adolescent and Young Adult) population, which appears to be a significant factor in the sales acceleration. While still operating at a loss, the continued revenue growth trajectory and shrinking losses suggest Fennec is making progress toward sustainable profitability.

Fennec Pharmaceuticals Inc. [1]